JPRN-UMIN000036202
招募中
4 期
ongitudinal analysis of bone microstructural changes under luseogliflozin treatment using second-generation High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT) in elderly patients with type 2 diabetes - Bone microstructural changse under luseogliflozin treatment
agasaki University Hospital0 个研究点目标入组 24 人2019年4月1日
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- type 2 diabetes
- 发起方
- agasaki University Hospital
- 入组人数
- 24
- 状态
- 招募中
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- 未提供
排除标准
- •(1\) Previous history of treatment with SGLT2 inhibitors (2\) Complicated with bone metabolic disorders including osteomalacia, thyroid dysfunction, hyperparathyroidism or hypoparathyroidism that require any medical treatments (3\) Administered any treatments for osteoporosis described below at present or within the past 12 months before enrolled into the study; bisphosphonate, vitamin D preparation, vitamin K preparation, calcium preparation, selective estrogen receptor modulator (SERM), anti\-RANKL antibody (denosumab), anti\-sclerostin antibody (romosozumab) or parathyroid hormone (teriparatide) (4\) Treated with estrogen or testosterone (5\) Complicated with diabetic retinopathy or/and diabetic neuropathy requiring therapeutic intervention (6\) Sever renal dysfunction with eGFR \<30 ml/min/1\.73 m2 (7\) Anemia with hemoglobin level under 10 g/dL (8\) Complicated with malignancy (9\) Hypersensitivity or allergy to the study drugs including luseogliflozin or metformin (10\) Taking alcohol more than 20 g/day (11\) Smoking cigarette within one year before enrolled into the study (12\) Participated in other clinical trials within 6 months before enrolled into the study (13\) Complicated with chronic liver disease with Child\-Pugh score of more than or equal to 6 points. (14\) BMI \<18\.5 kg/m2 (15\) Judged as an unsuitable participant by the researchers.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and PlaceboOsteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. Postmenopausal women with a diagnosis of osteopenia (T score between –2.5 and –1.0 based on the World Health Organization classification) may also be at risk of fracture.MedDRA version: 7.0 Level: PT Classification code 10031285EUCTR2005-003033-41-GBProcter & Gamble Technical Centres Limited156
进行中（未招募）
不适用
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing Weekly Oral Risedronate 35 mg and PlaceboEUCTR2005-003033-41-DEProcter & Gamble Technical Centres Limited156
招募中
不适用
Analysis of physiological markers, physical fitness, self-esteem and self-image in elderly people undergoing adapted TaekwondoRBR-5jzcc5qniversidade Estácio de Sá
已完成
不适用
Analyses of factors involved in bone remodeling and inflammation in Ankylosing Spondylitis (AS) patients undergoing etanercept therapyM45.00DRKS00004838Rheumazentrum Prof. Dr. med. G. Neeck56
招募中
不适用
Clinical investigation of change of bone-related marker between denosumab and zoledronic acid in patients with treatment-naive,bone-metastasis prostate cancer:prospective, multiinstitutional,cohort studytreatment-naive prostate cancer with bone metastasisJPRN-UMIN000018268Department of Renal and Urologic Surgery, Asahikawa Medical University50